ZURICH, Sept 20 – Novartis has increased its stockpiles of pharmaceuticals in the United States and is well prepared should its products be hit by President Donald Trump’s tariffs, its chief executive said in an interview published on Saturday. Pharmaceuticals are currently exempt from the 39% tariffs Washington imposed on Switzerland last month, although the industry is awaiting the outcome …
Read More »FDA targets Lilly, Novartis, BMS and more in deluge of marketing letters Fierce Pharma FDA takes aim at Hims & Hers, weight loss drugs in new advertising blitz AP News Hims & Hers Stock: How It Found Itself in the FDA’s Crosshairs Barron’s Opinion | I Run the F.D.A. Pharma Ads Are Hurting Americans. The New York Times U.S. FDA sends drug advertising warning …
Read More »Novartis assembles 2nd molecular glue deal with Monte Rosa, this one worth up to $5.7B Fierce Biotech Monte Rosa Therapeutics Announces Collaboration with Novartis for Degraders to Treat Immune-mediated Diseases GlobeNewswire Novartis signs up to $5.7 billion licensing deal with Monte Rosa Therapeutics Yahoo Finance Updated: Novartis extends deal spree with $120M for Monte Rosa’s immune degraders Endpoints News Novartis dives deeper into protein …
Read More »
Swiss giant drug producer Novartis (NVS) has found a new destination for its recent partnership spree. On Monday, Monte Rosa Therapeutics (GLUE), a Massachusetts-based biotech company, disclosed its second deal with Novartis, with Monte’s shares exploding over 50% in early trading to more than $7. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing …
Read More »
(Reuters) – Swiss drugmaker Novartis and drug developer Monte Rosa Therapeutics signed a licensing deal worth up to $5.7 billion on Monday to develop drugs for immune-mediated diseases. Under the agreement, Monte Rosa will receive an upfront payment of $120 million and could earn milestone payments and royalties that lift the total value to as much as $5.7 billion. Shares …
Read More »Novartis Agrees to Buy Tourmaline Bio in $1.4 Billion-Dollar Deal The Wall Street Journal Novartis to acquire Tourmaline Bio, complementing cardiovascular pipeline with pacibekitug for the treatment of atherosclerotic cardiovascular disease (ASCVD) Novartis This Biopharma Stock Is Soaring 58%. Novartis Is Acquiring It. Barron’s Novartis to buy Tourmaline Bio, gaining promising heart medicine statnews.com Novartis spends $1.4B for Tourmaline and cardiovascular med that impressed …
Read More »
Tourmaline Bio is a clinical-stage biopharmaceutical company developing pacibekitug, an anti-IL-6 mAb, as a treatment option for atherosclerotic cardiovascular disease Pacibekitug is a promising targeted therapy with the potential to reduce systemic inflammation—an independent and significant driver of cardiovascular risk—addressing a critical unmet need in ASCVD treatment Offer price of USD 48 per share valuing the company at approximately …
Read More »
Ad hoc announcement pursuant to Art. 53 LR NEPTUNUS-1 and NEPTUNUS-2 are the first ever global phase III trials to demonstrate statistically significant reduction in disease activity for Sjögren’s disease1 Ianalumab has the potential to become the first and only targeted treatment approved for patients with Sjögren’s disease Ianalumab was well tolerated and demonstrated a favorable safety profile in Sjögren’s …
Read More »
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Today we talk about the midsummer chill in the biotech market here in my home town of San Diego. Also, we learn that it was FDA cancer chief Richard Pazdur’s intervention that contributed to the rejection of Replimune’s melanoma drug …
Read More »